Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has earned an average rating of “Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $25.20.
Several research firms have recently weighed in on ATXS. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer upped their target price on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, TD Cowen assumed coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock.
View Our Latest Stock Report on Astria Therapeutics
Institutional Trading of Astria Therapeutics
Astria Therapeutics Stock Down 0.1 %
Shares of Astria Therapeutics stock opened at $10.62 on Tuesday. The stock’s fifty day moving average is $11.15 and its two-hundred day moving average is $11.07. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The company has a market capitalization of $583.18 million, a PE ratio of -4.58 and a beta of 0.71.
Astria Therapeutics (NASDAQ:ATXS – Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts anticipate that Astria Therapeutics will post -1.66 earnings per share for the current year.
About Astria Therapeutics
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
- Five stocks we like better than Astria Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- 3 Leveraged ETFs to Multiply Returns
- Insider Trades May Not Tell You What You Think
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Comparing and Trading High PE Ratio Stocks
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.